Checkpoint inhibitor therapies have revolutionized cancer treatment by enhancing the immune system's ability to target and destroy cancer cells. By boosting the immune response, these therapies have made significant strides in prolonging the lives of patients with various types of cancer. These
Multiple myeloma (MM), a complex form of blood cancer originating in plasma cells, relentlessly impairs blood counts and immune functions. Despite breakthroughs in treatment modalities, MM largely remains incurable, with patients often enduring cycles of remission interrupted by relapses. This
The fight against advanced melanoma, a particularly aggressive form of skin cancer, has long been hindered by the cancer's ability to develop resistance to conventional treatments. However, a groundbreaking study led by QUT researchers at Brisbane's Translational Research Institute (TRI) offers a
Lambert-Eaton myasthenic syndrome (LEMS) is a rare and debilitating autoimmune disorder where the immune system mistakenly attacks the body's own tissues, specifically targeting voltage-gated calcium channels (VGCCs) on nerve cells. This disruption in nerve-muscle communication results in muscle
Washington University School of Medicine in St. Louis (WashU Medicine) has been awarded a significant five-year, $10.8 million grant from the National Cancer Institute (NCI) of the National Institutes of Health (NIH). This funding renewal aims to advance the institution's ongoing research in
Researchers at the Perelman School of Medicine at the University of Pennsylvania have made a significant breakthrough in personalized medicine and cancer treatment. By using patient-derived glioblastoma (GBM) organoids, they have developed a method to model patient responses to CAR-T cell therapy
